Ad hoc News
Zur Rose Group: Excellent starting position for e-prescriptions set up and ecosystem strategy successfully continued
Zur Rose Group successfully completed capital increase from authorised capital and sets placement price at CHF 290 per new share
Zur Rose Group decides on capital increase from authorised capital and starts accelerated bookbuilding to make full use of increasing market opportunities
Zur Rose Group: Board of Directors nominates Walter Oberhänsli as Chairman and appoints Walter Hess as new CEO
At the moment no ad-hoc announcements are available.